Global Soft Tissue Sarcoma Market is segmented by Disease Type (Local sarcoma, Regional sarcoma, Metastatic sarcoma), by Treatment (Radiation Therapy, Chemotherapy, Targeted therapy, Anti-angiogenesis drugs, and Other Treatments), By End-User (Hospitals, Oncology Centers and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Soft Tissue Sarcoma Market Overview
Report on Global Soft Tissue Sarcoma by DataM Intelligence estimates the market to grow at a CAGR 8.8% during the forecast period 2023-2030. Demand from Hospitals, and Oncology Centers in North America is booming. Competitive rivalry intensifies with GlaxoSmithKline Plc, Celgene Corporation, Merck KGaA and others operating in the market.
- Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
- There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.
Soft Tissue Sarcoma Market Scope and Summary
Metrics
|
Details
|
Market CAGR
|
8.8%
|
Segments Covered
|
By Disease Type, By Treatment, By End User, and By Region
|
Report Insights Covered
|
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
|
Fastest Growing Region
|
Asia Pacific
|
Largest Market Share
|
North America
|
For more insights - Download Sample
Soft Tissue Sarcoma Market Analysis
Soft Tissue Sarcoma Geography Shares
- Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
- The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
- Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
- In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
- The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Buy this report
Enterprise User
$7850$6280
Proceed to Buy
Request new version
Who are the key players in Global Soft Tissue Sarcoma Market ?
Major players are Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc, Johnson & Johnson Services Inc, Teva Pharmaceutical Industries Ltd, Celgene Corporation, Bristol-Myers Squibb Company, Threshold Pharmaceuticals Inc, and Merck KGaA.
Which region controlled the Global Soft Tissue Sarcoma Market during 2023-2030?
North America region Controls and dominates the Global Global Soft Tissue Sarcoma Market.